176 related articles for article (PubMed ID: 26568602)
1. Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice.
Weycker D; Chandler D; Barron R; Xu H; Wu H; Edelsberg J; Lyman GH
J Oncol Pharm Pract; 2017 Jan; 23(1):33-42. PubMed ID: 26568602
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
3. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
4. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
5. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
[TBL] [Abstract][Full Text] [Related]
6. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
7. Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.
Li X; Luthra R; Morrow PK; Fisher MD; Reiner M; Barron RL; Langeberg WJ
J Oncol Pharm Pract; 2016 Oct; 22(5):679-89. PubMed ID: 26378158
[TBL] [Abstract][Full Text] [Related]
8. Rational selection of patients for antibacterial prophylaxis after chemotherapy.
Cullen MH; Billingham LJ; Gaunt CH; Steven NM
J Clin Oncol; 2007 Oct; 25(30):4821-8. PubMed ID: 17947731
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
[TBL] [Abstract][Full Text] [Related]
10. Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.
Sosa R; Li S; Molony JT; Liu J; Stryker S; Collins AJ
Support Care Cancer; 2017 Oct; 25(10):3123-3132. PubMed ID: 28456908
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
12. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.
Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
J Oncol Pract; 2015 Jan; 11(1):47-54. PubMed ID: 25491042
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
14. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Weycker D; Edelsberg J; Kartashov A; Barron R; Lyman G
Chemotherapy; 2012; 58(1):8-18. PubMed ID: 22343254
[TBL] [Abstract][Full Text] [Related]
15. The assessment and management of chemotherapy-related toxicities in patients with breast cancer, colorectal cancer, and Hodgkin's and non-Hodgkin's lymphomas: A scoping review.
Fox P; Darley A; Furlong E; Miaskowski C; Patiraki E; Armes J; Ream E; Papadopoulou C; McCann L; Kearney N; Maguire R
Eur J Oncol Nurs; 2017 Feb; 26():63-82. PubMed ID: 28069154
[TBL] [Abstract][Full Text] [Related]
16. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Cullen M; Steven N; Billingham L; Gaunt C; Hastings M; Simmonds P; Stuart N; Rea D; Bower M; Fernando I; Huddart R; Gollins S; Stanley A;
N Engl J Med; 2005 Sep; 353(10):988-98. PubMed ID: 16148284
[TBL] [Abstract][Full Text] [Related]
18. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma.
Goldspiel BR
Pharmacotherapy; 2004 Oct; 24(10):1347-57. PubMed ID: 15628832
[TBL] [Abstract][Full Text] [Related]
20. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
Al-Kali A; Ozer H
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
